logo

VALN

Valneva·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

VALN fundamentals

Valneva (VALN) expects to report earnings on Aug 12, 2025, with estimated revenue of 53.67M (YoY +30.52%), and EPS at -0.19 (YoY +52.50%).
Revenue estimate / YoY
53.67M
+30.52%
EPS estimate / YoY
-0.19
+52.50%
Report date
Aug 12, 2025
VALN Earnings Call Summary for Q2,2025
  • Revenue Surge: H1 2025 revenue up 37.8% to EUR 97.6 million, driven by 33.3% product sales growth.
  • Lyme Vaccine Milestone: Phase III study completed vaccination; Pfizer targets 2026 regulatory submissions.
  • IXCHIQ Regulatory Win: Restrictions lifted, enabling broader use in U.S. and Europe.
  • Shigella Progress: Phase II infant study underway, with efficacy data expected early 2026.
  • Cash Strength: EUR 160 million cash, with >50% reduction in operating cash burn YoY.
EPS
Revenue

Revenue & Expenses

VALN has released its 2025 Q3 earnings report, with revenue of 34.51M, reflecting a YoY change of -32.42%, and net profit of -52.05M, showing a YoY change of -405.66%. The Sankey diagram below clearly presents VALN's revenue sources and cost distribution.

Key Indicators

Valneva (VALN) key financial stats and ratios, covering profitability, financial health, and leverage.
Valneva (VALN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Valneva (VALN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Valneva (VALN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Valneva (VALN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Valneva (VALN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield